Aptevo discloses $2.3 million current ATM offering capacity as of Oct 30, 2026

Aptevo Therapeutics filed a prospectus supplement dated October 30, 2026 updating the terms of its at-the-market stock offering conducted through Roth Capital Partners. The company said it filed the supplement to revise the amount it may offer and sell under its registration statement following an increase in the aggregate market value of its common stock held by non-affiliates, known as its public float.¹

Under SEC rules governing companies with public float below $75,000,000, Aptevo may not sell securities in a public primary offering worth more than one-third of its public float in any 12-month period.¹ The company calculated its public float as of October 30, 2026 at $6,929,502, based on 2,665,193 shares held by non-affiliates and a $2.60 per-share price as of September 2, 2026.¹ Aptevo stated it had sold $0 in securities under this rule during the trailing 12-month period ending on the date of the filing.¹

As a result, Aptevo said it may currently offer and sell additional shares of common stock with an aggregate offering price of up to $2,309,834 through Roth as sales agent.¹ The company said that if its public float increases enough to allow a greater sales amount, it will file another prospectus supplement before making further sales.¹

The filing also disclosed prior activity under the sales agreement. As of the date of the supplement, Aptevo had sold 303,157 shares of common stock at an aggregate gross offering price of $38.92 under the agreement, for aggregate gross proceeds of $11,799,276.¹

Aptevo's common stock trades on The Nasdaq Capital Market under the symbol APVO, and last closed at $1.34 per share on October 30, 2026.¹